-
Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress
SHANGHAI, Oct. 15, 2025 -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical research results of its novel B7-H3-targeting ADC (R&D code: 7MW3711) for multiple advanced solid tumors, will be presented as a poster at the European Society for Medical Oncology (ESMO) Congress 2025. As of Sep. 15, 2025, 74 patients with advanced solid tumor were enrolled and treated with 7MW3711 in the phase I/II study. Among 54 patients treated at 4.0 mg/kg or above and reaching tumor assessment, 19 partial responses (PRs) or complete resp
- 김갑성 기자
- 2025-10-15 00:00
-
Benchling Reveals the Next Chapter of R&D at Benchtalk 2025
Benchling AI debuts alongside major new capabilities for antibody discovery, automated data analysis, and development BOSTON, Oct. 14, 2025 -- Benchling today unveiled major new capabilities at Benchtalk, its annual customer conference. These new releases are designed to help biotech companies automate R&D workflows and bring the power of AI into scientists' everyday work. "At Benchling, we are on a mission to unlock the power of biotechnology. Advances in AI will help our customers get life-saving medicines to patients faster," said Sajith Wickramasekara,
- 김갑성 기자
- 2025-10-14 21:14
-
Co-PSMA trial achieves primary endpoint
SYDNEY, Oct. 14, 2025 -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT), led by Prof Louise Emmett at St Vincent's Hospital Sydney, has achieved its primary endpoint with a statistically significant higher number of prostate-specific membrane antigen (PSMA)-positive prostate cancer lesions detected using 64Cu-
- 김갑성 기자
- 2025-10-14 21:03
-
HEX Launches Next-Generation Protective Gear with NBA Superstar Kyrie Irving
Irving joins HEX to showcase the brand's most advanced protective line yet, engineered with cutting-edge design to deliver lightweight, flexible, and breathable protection for the modern athlete. FOUNTAIN VALLEY, Calif., Oct. 14, 2025 -- HEX, the next-generation protective gear line from McDavid, today announced the launch of its most advanced performance apparel collection yet, engineered with cutting-edge design to deliver lightweight, flexible, and breathable protection for athletes who compete at the highest level. NBA superstar Kyrie Irving will play a leading role in show
- 황정호 기자
- 2025-10-14 21:01
-
IMG Expands iTravelInsured Choice with New Add-Ons and Specialized Plans
INDIANAPOLIS, Oct. 14, 2025 -- IMG (International Medical Group) has announced new optional coverage add-ons to its most popular travel insurance plan, iTravelInsured Choice, and the launch of two new products. Travelers now have the option to expand their iTravelInsured Choice coverage in several key areas through a variety of add-ons at an additional cost: Cancel For Any Reason (CFAR) & Interruption For Any Reason (IFAR) coverage Increased medical coverage Additional benefits and covered reasons specific to cruises Enhanced benefits to accommodate adventur
- 황정호 기자
- 2025-10-14 21:00
-
Securing Global Financial Transactions: ReconArt Achieves 70% Faster Compliance with Armor Defense and Oracle
DALLAS, Oct. 14, 2025 -- ReconArt, a leading provider of enterprise-class reconciliation and financial solutions, announced it has selected Armor Defense's Managed Detection and Response (MDR) services on Oracle Cloud Infrastructure (OCI) to secure its high-performance financial platform. In financial services, precision and resilience are non-negotiable. A single missed transaction or failed control can trigger financial loss, regulatory action, or lasting reputational damage. Sustaining this precision and resilience demands Armor's advanced defense - anticipating and neutrali
- 황정호 기자
- 2025-10-14 21:00
-
Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025
AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, advanced ccRCC, and NSCLC with data featured in both oral and poster presentations SEOUL, South Korea, Oct. 14, 2025 -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the presentation of three studies at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. All three studies highlight how Lunit's AI pathology solution, Lunit SCOPE IO®, can identify biomarkers that p
- 김갑성 기자
- 2025-10-14 21:00
-
bunq Accelerates Global Expansion with Premium Rewards Proposition Powered by Ascenda
Neobank elevates customer value and deepens engagement through Ascenda's global rewards network NEW YORK, Oct. 14, 2025 -- Ascenda, the loyalty company that powers growth for the world's leading financial institutions, today announced its new partnership with bunq, Europe's second-largest neobank. The collaboration elevates bunq's loyalty program, unlocking superior rewards that power its users' international lifestyle. bunq's skyrocketing trajectory - marked by its recent 20 million user milestone and plans for US expansion - is underpinned by a relentless
- 황정호 기자
- 2025-10-14 21:00
-
DXC Named a Leader in Property and Casualty Insurance in Everest Group Assessment of BPS Providers
[ 메디채널 황정호 기자 ] Recognition highlights DXC's market-leading technology, AI innovation, and industry expertise ASHBURN, Va., Oct. 14, 2025 -- DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, has been named a Leader by global research firm Everest Group in its new report, "Property and Casualty (P&C) Insurance BPS PEAK Matrix® Assessment 2025." DXC was also awarded Star Performer status for demonstrating forward and upward movement from the previous edition of the report published in 2023. The Everest Group report h
- 황정호 기자
- 2025-10-14 21:00
-
Pictor's Proteomics Platform Offers Promising Advancement for Detecting Mycoplasma bovis in Cattle
New research highlights the Pictor PictVet™ Mycoplasma bovis IgG Multiplex ELISA's enhanced analytical performance through multiplexing and its potential to enhance global disease management. CARLSBAD, Calif., Oct. 14, 2025 -- Mycoplasma bovis is a devastating pathogen that threatens cattle health and productivity worldwide. In the United States alone, economic losses due to M. bovis mastitis are estimated to be above $100 million annually. While Mycoplasma bovis is not a human infection risk, it is a public health systems risk — through antimicrobial resistance, food security
- 김갑성 기자
- 2025-10-14 21:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 8대한약물영양의학회 2020년 추계학술대회
- 92021년 대학생기자단 모집
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-15_WED
2025-10-14_TUE
- Benchling Reveals the Next Chapter of R&D at Benchtalk 2025 21:14
- Co-PSMA trial achieves primary endpoint 21:03
- HEX Launches Next-Generation Protective Gear with NBA Superstar Kyrie Irving 21:01
- IMG Expands iTravelInsured Choice with New Add-Ons and Specialized Plans 21:00
- Securing Global Financial Transactions: ReconArt Achieves 70% Faster Compliance with Armor Defense and Oracle 21:00
- Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025 21:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 15일 01시 40분